Literature DB >> 10321973

Regulation of pteridine-requiring enzymes by the cofactor tetrahydrobiopterin.

T Nagatsu1, H Ichinose.   

Abstract

Tetrahydrobiopterin (BH4) is synthesized from guanosine triphosphate (GTP) by GTP cyclohydrolase I (GCH), 6-pyruvoyltetrahydropterin synthase (PTS), and sepiapterin reductase (SPD). GCH is the rate-limiting enzyme. BH4 is a cofactor for three pteridine-requiring monooxygenases that hydroxylate aromatic L-amino acids, i.e., tyrosine hydroxylase (TH), tryptophan hydroxylase (TPH), and phenylalanine hydroxylase (PAH), as well as for nitric oxide synthase (NOS). The intracellular concentrations of BH4, which are mainly determined by GCH activity, may regulate the activity of TH (an enzyme-synthesizing catecholamines from tyrosine), TPH (an enzyme-synthesizing serotonin and melatonin from tryptophan), PAH (an enzyme required for complete degradation of phenylalanine to tyrosine, finally to CO2 + H2O), and also the activity of NOS (an enzyme forming NO from arginine), Dominantly inherited hereditary progressive dystonia (HPD), also termed DOPA-responsive dystonia (DRD) or Segawa's disease, is a dopamine deficiency in the nigrostriatal dopamine neurons, and is caused by mutations of one allele of the GCH gene. GCH activity and BH4 concentrations in HPD/DRD are estimated to be 2-20% of the normal value. By contrast, recessively inherited GCH deficiency is caused by mutations of both alleles of the GCH gene, and the GCH activity and BH4 concentrations are undetectable. The phenotypes of recessive GCH deficiency are severe and complex, such as hyperphenylalaninemia, muscle hypotonia, epilepsy, and fever episode, and may be caused by deficiencies of various neurotransmitters, including dopamine, norepinephrine, serotonin, and NO. The biosynthesis of dopamine, norepinephrine, epinephrine, serotonin, melatonin, and probably NO by individual pteridine-requiring enzymes may be differentially regulated by the intracellular concentration of BH4, which is mainly determined by GCH activity. Dopamine biosynthesis in different groups of dopamine neurons may be differentially regulated by TH activity, depending on intracellular BH4 concentrations and GCH activity. The nigrostriatal dopamine neurons may be most susceptible to a partial decrease in BH4, causing dopamine deficiency in the striatum and the HPD/DRD phenotype.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10321973     DOI: 10.1007/BF02741379

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  83 in total

1.  THE STRUCTURE OF THE PHENYLALANINE-HYDROXYLATION COFACTOR.

Authors:  S KAUFMAN
Journal:  Proc Natl Acad Sci U S A       Date:  1963-12       Impact factor: 11.205

2.  Mutant GTP cyclohydrolase I mRNA levels contribute to dopa-responsive dystonia onset.

Authors:  M Hirano; Y Tamaru; H Ito; S Matsumoto; T Imai; S Ueno
Journal:  Ann Neurol       Date:  1996-11       Impact factor: 10.422

Review 3.  Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation.

Authors:  R E Zigmond; M A Schwarzschild; A R Rittenhouse
Journal:  Annu Rev Neurosci       Date:  1989       Impact factor: 12.449

4.  Differential splicing of the GTP cyclohydrolase I RNA in dopa-responsive dystonia.

Authors:  M Hirano; Y Imaiso; S Ueno
Journal:  Biochem Biophys Res Commun       Date:  1997-05-19       Impact factor: 3.575

Review 5.  Biosynthesis and metabolism of tetrahydrobiopterin and molybdopterin.

Authors:  C A Nichol; G K Smith; D S Duch
Journal:  Annu Rev Biochem       Date:  1985       Impact factor: 23.643

6.  Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene.

Authors:  H Ichinose; T Ohye; E Takahashi; N Seki; T Hori; M Segawa; Y Nomura; K Endo; H Tanaka; S Tsuji
Journal:  Nat Genet       Date:  1994-11       Impact factor: 38.330

7.  Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development.

Authors:  Q Y Zhou; C J Quaife; R D Palmiter
Journal:  Nature       Date:  1995-04-13       Impact factor: 49.962

8.  Dissociated release of tetrahydrobiopterin and nitric oxide by lipopolysaccharide from mouse neuroblastoma cells.

Authors:  S Yoshida; A Ota; K Umezawa; T Nagatsu
Journal:  Neurosci Lett       Date:  1996-07-12       Impact factor: 3.046

9.  Tetrahydrobiopterin, the cofactor for aromatic amino acid hydroxylases, is synthesized by and regulates proliferation of erythroid cells.

Authors:  K Tanaka; S Kaufman; S Milstien
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

10.  Regulation of tetrahydrobiopterin biosynthesis in cultured dopamine neurons by depolarization and cAMP.

Authors:  M Zhu; K Hirayama; G Kapatos
Journal:  J Biol Chem       Date:  1994-04-22       Impact factor: 5.157

View more
  17 in total

Review 1.  Mechanisms of storage and exocytosis in neuroendocrine tumors.

Authors:  Manfred Gratzl; Martin Breckner; Christian Prinz
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

2.  Biochemical characterization of the tetrahydrobiopterin synthesis pathway in the oleaginous fungus Mortierella alpina.

Authors:  Hongchao Wang; Bo Yang; Guangfei Hao; Yun Feng; Haiqin Chen; Lu Feng; Jianxin Zhao; Hao Zhang; Yong Q Chen; Lei Wang; Wei Chen
Journal:  Microbiology (Reading)       Date:  2011-08-18       Impact factor: 2.777

3.  Elevated plasma phenylalanine in severe malaria and implications for pathophysiology of neurological complications.

Authors:  Bert K Lopansri; Nicholas M Anstey; Gregory J Stoddard; Esther D Mwaikambo; Craig S Boutlis; Emiliana Tjitra; Helena Maniboey; Maurine R Hobbs; Marc C Levesque; J Brice Weinberg; Donald L Granger
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

4.  Arg375 tunes tetrahydrobiopterin functions and modulates catalysis by inducible nitric oxide synthase.

Authors:  Zhi-Qiang Wang; Jesús Tejero; Chin-Chuan Wei; Mohammad Mahfuzul Haque; Jerome Santolini; Mohammed Fadlalla; Ashis Biswas; Dennis J Stuehr
Journal:  J Inorg Biochem       Date:  2011-11-23       Impact factor: 4.155

5.  Alterations in the reduced pteridine contents in the cerebrospinal fluids of LRRK2 mutation carriers and patients with Parkinson's disease.

Authors:  Hiroshi Ichinose; Ken-Ichi Inoue; Shinobu Arakawa; Yuki Watanabe; Hiroki Kurosaki; Shoko Koshiba; Eldbjorg Hustad; Masahiko Takada; Jan O Aasly
Journal:  J Neural Transm (Vienna)       Date:  2017-09-01       Impact factor: 3.575

6.  Fluvoxamine, a selective serotonin reuptake inhibitor, suppresses tetrahydrobiopterin levels and dopamine as well as serotonin turnover in the mesoprefrontal system of mice.

Authors:  H Miura; H Qiao; T Kitagami; T Ohta; N Ozaki
Journal:  Psychopharmacology (Berl)       Date:  2004-07-29       Impact factor: 4.530

7.  Estradiol increases guanosine 5'-triphosphate cyclohydrolase expression via the nitric oxide-mediated activation of cyclic adenosine 5'-monophosphate response element binding protein.

Authors:  Xutong Sun; Sanjiv Kumar; Jing Tian; Stephen M Black
Journal:  Endocrinology       Date:  2009-04-23       Impact factor: 4.736

8.  Epistasis between polymorphisms in COMT, ESR1, and GCH1 influences COMT enzyme activity and pain.

Authors:  Shad B Smith; Ilkka Reenilä; Pekka T Männistö; Gary D Slade; William Maixner; Luda Diatchenko; Andrea G Nackley
Journal:  Pain       Date:  2014-09-16       Impact factor: 6.961

9.  Improved nutritional management of phenylketonuria by using a diet containing glycomacropeptide compared with amino acids.

Authors:  Sandra C van Calcar; Erin L MacLeod; Sally T Gleason; Mark R Etzel; Murray K Clayton; Jon A Wolff; Denise M Ney
Journal:  Am J Clin Nutr       Date:  2009-02-25       Impact factor: 7.045

10.  GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer.

Authors:  Jin-Li Wei; Si-Yu Wu; Yun-Song Yang; Yi Xiao; Xi Jin; Xiao-En Xu; Xin Hu; Da-Qiang Li; Yi-Zhou Jiang; Zhi-Ming Shao
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.